Skba Capital Management LLC Purchases 21,400 Shares of Pfizer Inc. (NYSE:PFE)

Skba Capital Management LLC boosted its position in Pfizer Inc. (NYSE:PFE) by 5.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 450,250 shares of the biopharmaceutical company’s stock after purchasing an additional 21,400 shares during the quarter. Pfizer makes up 1.9% of Skba Capital Management LLC’s portfolio, making the stock its 20th biggest position. Skba Capital Management LLC’s holdings in Pfizer were worth $11,945,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Retirement Wealth Solutions LLC purchased a new position in Pfizer during the 4th quarter valued at about $26,000. Rialto Wealth Management LLC bought a new position in shares of Pfizer during the fourth quarter valued at approximately $26,000. Kohmann Bosshard Financial Services LLC purchased a new position in shares of Pfizer during the fourth quarter valued at approximately $28,000. Noble Wealth Management PBC bought a new stake in shares of Pfizer in the 4th quarter worth approximately $31,000. Finally, Curio Wealth LLC purchased a new stake in shares of Pfizer in the 4th quarter worth approximately $32,000. Institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

PFE has been the subject of a number of recent research reports. Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. Bank of America reiterated a “neutral” rating and issued a $29.00 price target on shares of Pfizer in a research note on Tuesday, December 10th. UBS Group reduced their price objective on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research note on Wednesday, January 8th. Truist Financial dropped their target price on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday, December 18th. Finally, Citigroup decreased their price objective on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a report on Tuesday, January 28th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have issued a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Stock Performance

PFE stock opened at $25.20 on Monday. The company has a market cap of $142.93 billion, a P/E ratio of 17.87, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54. The stock’s fifty day moving average price is $26.06 and its 200-day moving average price is $26.90.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. During the same period in the previous year, the company posted $0.10 EPS. The business’s quarterly revenue was up 24.7% compared to the same quarter last year. On average, equities analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Insider Buying and Selling at Pfizer

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of the company’s stock in a transaction dated Thursday, February 13th. The shares were acquired at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the purchase, the director now directly owns 27,707 shares of the company’s stock, valued at $710,684.55. The trade was a 235.84 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.06% of the stock is owned by corporate insiders.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.